Ontario First in Canada to Provide Coverage for New ALS Treatment

Our government is committed to connecting more Ontarians to the care they need.

Our government is giving people access to more treatment options by expanding public access to life-saving medication and therapeutics. Expanding Ontario’s drug program to include Albrioza will ensure people living with Amyotrophic Lateral Sclerosis (ALS) will benefit from this new treatment sooner.

Albrioza is a new treatment options for those living with ALS, also known as Lou Gehrig’s disease. Ontarians and their families are encouraged to reach out to their healthcare providers to help determine if Albrioza is a suitable treatment option for them.

Learn more: https://news.ontario.ca/en/release/1003213/ontario-first-in-canada-to-provide-coverage-for-new-als-treatment